Provided by Tiger Trade Technology Pte. Ltd.

Oculis

12.96
-0.2200-1.67%
Pre-market: 13.210.2530+1.95%04:00 EDT
Volume:192.37K
Turnover:2.54M
Market Cap:800.05M
PE:-7.56
High:13.42
Open:13.25
Low:12.90
Close:13.18
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:1.19
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.93
PE(LYR):-5.43

Loading ...

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

GlobeNewswire
·
Aug 03

Oculis to Acquire Mitie in £3.1 Billion Deal, Sending Target's Shares Soaring 40%

Deep News
·
Jul 21

Mitie Shares Soar on $4.2 Billion Takeover by OCS

Dow Jones
·
Jul 21

Mitie Halts £100m Share Buyback After Recommended OCS Takeover Offer

TIPRANKS
·
Jul 21

Village Farms Unveils Super Toast Bites, a New Line of Cannabis-Infused Gummies

GlobeNewswire
·
Jul 14

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jul 09

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

GlobeNewswire
·
Jul 02

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch

TIPRANKS
·
Jul 02

Nordic Shares Gain; Oculis Holding Tops Leaders

Dow Jones
·
Jul 01

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway

TIPRANKS
·
Jun 26

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 16

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 11

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

GlobeNewswire
·
Jun 11

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 11

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)

TIPRANKS
·
Jun 11

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jun 10

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

GlobeNewswire
·
Jun 09

Oculis Stock Plummets After Phase 3 Trial Failures, Prompting Multiple Law Firm Probes

Deep News
·
Jun 09

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

GlobeNewswire
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

TIPRANKS
·
Jun 06